Skip to content

Physiological Signals, Activity and Posture for Surface Mounted Insertable Cardiac Monitor in Heart Failure Study

Physiological Signals, Activity and Posture for Surface Mounted Insertable Cardiac Monitor in Heart Failure Study

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT04112576
Acronym
HAPI-HF
Enrollment
100
Registered
2019-10-02
Start date
2020-07-23
Completion date
2022-05-11
Last updated
2023-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Heart Failure, Diastolic, Heart Failure, Systolic

Keywords

echocardiogram

Brief summary

To characterize the physiological signals collected from a Wearable Cardiac Monitor (WCM) prototype device in subjects with heart failure and preserved ejection fraction (HFpEF) and compare against signals from subjects with heart failure and reduced ejection fraction (HFrEF). To evaluate the relationship of physiological signals measured from a wearable cardiac monitor (WCM) prototype device with ECHO measures of systolic and diastolic function

Detailed description

This is a non-randomized, feasibility study that will enroll up to 100 participants clinically diagnosed with HFpEF or HFrEF. Approximately 70% of participants will have HFpEF and 30% will have HFrEF. There will be one study visit per participant. The study visit includes device placement and data collection during postural changes. Echocardiograms will also be collected throughout the study and at least 30% of participants will undergo a submaximal exercise test. The device will then be removed.

Interventions

Participants will be fitted with a wearable cardiac monitor placed on the skin that measures physiologic signals.

Sponsors

Boston Scientific Corporation
Lead SponsorINDUSTRY

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
21 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Patients with NYHA class II or III heart failure defined by symptoms and signs of heart failure * Documented episode of decompensated heart failure in the past 3 years, which either: a) resulted in a hospital admission (primary diagnosis) or b) was treated in out-patient clinic * HFrEF defined by documented evidence of EF ≤ 40% OR * HFpEF defined by documented evidence of: * EF ≥ 50% and no prior record of EF \< 40% * Evidence of relevant structural heart disease or diastolic dysfunction on echocardiographic as defined in the 2016 ESC guidelines * Able to understand and willing to provide written informed consent to participate in the trial * Age 21 years old or greater * Willing and able to participate in the required testing

Exclusion criteria

* Prior hospitalization, CV event or surgery within 6 weeks * Subject is currently enrolled in another clinical trial (excluding registries) that may interfere with the placement of the study system or include the usage of investigational drugs. * Patients with Active Implantable Medical Devices * Known allergy to materials used in the study (adhesive tape, titanium, ECG electrodes) * Have a prosthetic cardiac valve, previously underwent cardiac valve surgery or have hemodynamically unstable (as judged by local investigator) valvular disease * Subject is pregnant as indicated by patient record * Patients with rash or open wound on torso locations where investigational devices will be placed * Patient deemed as clinically unstable or unsuitable to perform prescribed testing as judged by the local investigator

Design outcomes

Primary

MeasureTime frameDescription
Physiologic Signal Detection12 monthsCharacterize differences in cardiac physiology and dynamics between heart failure with preserved ejection fraction and heart failure with reduced ejection fraction patient populations using a wearable cardiac monitor prototype device.

Countries

Singapore, Taiwan, United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026